Stock LXRX LEXICON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Lexicon Pharmaceuticals, Inc.

Equities

LXRX

US5288723027

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:30:00 03/05/2024 BST 		5-day change 1st Jan Change
1.74 USD +2.35% Intraday chart for Lexicon Pharmaceuticals, Inc. +10.13% +13.73%
05-02 Transcript : Lexicon Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024
05-02 Earnings Flash (LXRX) LEXICON PHARMACEUTICALS Posts Q1 Revenue $1.1M, vs. Street Est of $1.4M MT

Business Summary

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.

Number of employees: 285

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceutical Products
100.0 %
0 100.0 % 1 100.0 % +766.19%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 100.0 % 1 100.0 % +766.19%

Managers

Managers TitleAgeSince
Lonnel Coats CEO
 Chief Executive Officer 58 06/07/14
Jeffrey Wade DFI
 Director of Finance/CFO 59 31/12/98
Craig Granowitz CTO
 Chief Tech/Sci/R&D Officer 60 01/08/21
Lisa M. DeFrancesco IRC
 Investor Relations Contact 45 11-12
Tom Garner PRN
 Corporate Officer/Principal - 08/10/23
Wendy Mcdermott HRO
 Human Resources Officer - 31/12/21
Kristen Alexander AUD
 Comptroller/Controller/Auditor 56 31/05/17
Kenneth Kassler-Taub LAW
 General Counsel - 03/11/14
Brian Crum LAW
 General Counsel 51 31/12/00

Members of the board

Members of the board TitleAgeSince
Robert Lefkowitz BRD
 Director/Board Member 80 31/01/01
Ray Debbane CHM
 Chairman 69 31/07/07
Christopher Sobecki BRD
 Director/Board Member 65 27/08/07
Philippe Amouyal BRD
 Director/Board Member 65 31/07/07
Judith Swain BRD
 Director/Board Member 75 31/08/07
Lonnel Coats CEO
 Chief Executive Officer 58 06/07/14
Samuel Barker BRD
 Director/Board Member 81 29/02/00
Diane Sullivan BRD
 Director/Board Member 62 27/07/23

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 247,764,761 242,087,491 ( 97.71 %) 1,528,008 ( 0.6167 %) 97.71 %

Shareholders

NameEquities%Valuation
Invus Public Equities Advisors LLC
47.74 %
117,553,284 47.74 % 282 M $
Artal Group SA
47.74 %
117,553,284 47.74 % 282 M $
BVF, Inc.
9.924 %
24,435,632 9.924 % 59 M $
BlackRock Advisors LLC
2.689 %
6,621,889 2.689 % 16 M $
Vanguard Fiduciary Trust Co.
2.429 %
5,980,371 2.429 % 14 M $
JPMorgan Investment Management, Inc.
1.236 %
3,043,291 1.236 % 7 M $
NEA Management Co. LLC
0.9675 %
2,382,286 0.9675 % 6 M $
Geode Capital Management LLC
0.9539 %
2,348,916 0.9539 % 6 M $
Fidelity Management & Research Co. LLC
0.9245 %
2,276,468 0.9245 % 5 M $
STATE STREET CORPORATION
0.7685 %
1,892,319 0.7685 % 5 M $

Company contact information

Lexicon Pharmaceuticals, Inc.

2445 Technology Forest Boulevard 11th floor

77381-1160, The Woodlands

+

http://www.lexpharma.com
address Lexicon Pharmaceuticals, Inc.(LXRX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Lexicon Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1.74 USD
Average target price
5.25 USD
Spread / Average Target
+201.72%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
LEXICON PHARMACEUTICALS, INC. Stock Lexicon Pharmaceuticals, Inc.
+13.73% 428M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.43% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+8.96% 105B
ARGENX SE Stock argenx SE
+4.40% 22.94B
BIONTECH SE Stock BioNTech SE
-12.15% 22.34B
GENMAB A/S Stock Genmab A/S
-4.36% 19.25B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.08B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.04% 16.96B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.79% 14.16B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+38.61% 12.63B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. LXRX Stock
  4. Company Lexicon Pharmaceuticals, Inc.